Kailera Therapeutics has done one of the most expensive, unglamorous jobs in obesity drug development: it has filled its pivotal trials. In its November 4 third-quarter report, the company confirmed that its global Phase 3 program for ribupatide, a once-weekly GLP-1/GIP injection developed with China’s Hengrui Pharma, is fully enrolled across three trials totaling approximately 5,000 participants. A separate high-dose Phase 2b study testing as much as 20 mg is also full.
The catch is the calendar. The Phase 3 results are not expected until mid-2028, and Kailera recorded a net loss of nearly $96 million in the latest quarter. Its cash, cash equivalents and marketable securities totaled about $1.04 billion at the end of September, with management projecting enough funding to operate into mid-2028.
That combination—a large enrolled program, a substantial cash reserve and a long wait for decisive clinical evidence—captures the challenge facing the second wave of obesity-drug developers. Kailera is a particularly clear test of whether a molecule first advanced in China can become a global competitor in a market already dominated by established treatments.
Kailera’s 5,000-Patient Phase 3 Program Is Already Enrolled
The lead asset is ribupatide injection, also called KAI-9531 and known as HRS9531 in China. It is designed to activate both the GLP-1 and GIP receptors, the same two hormonal targets used by tirzepatide, the active ingredient in Lilly’s Mounjaro and Zepbound.
Kailera’s global program, KaiNETIC, includes three randomized, double-blind, placebo-controlled Phase 3 studies: KaiNETIC-1, KaiNETIC-2 and KaiNETIC-3. Together, they enrolled approximately 5,000 adults with obesity or overweight, testing weekly doses up to 10 mg over 76 weeks. The studies address different populations, including people with type 2 diabetes and adults with more severe obesity.
The enrollment milestone itself is not new. Kailera announced completion on September 30, 2026. The November quarterly report reconfirmed it and retained the expected mid-2028 data timeline.
The distinction matters. Enrollment means a company has recruited participants into the studies, not that the treatment has met the studies’ endpoints. Kailera has reduced one major source of trial-execution uncertainty, but the efficacy and safety results remain ahead.
Filling three trials is a real achievement. It is not the same thing as winning them.
What Ribupatide’s Chinese Clinical Results Actually Show
The scientific foundation for ribupatide comes primarily from clinical studies conducted in China by Hengrui Pharma. The most important late-stage result so far is GEMINI-1, a 48-week Phase 3 study in 567 adults with overweight or obesity.
Hengrui and Kailera reported that the study met both co-primary endpoints. In the treatment-policy analysis, participants receiving the highest tested dose, 6 mg, lost an average of 17.7% of body weight, compared with 1.4% on placebo. In a separate hypothetical-strategy analysis, weight loss reached 19.2% versus 1.4% for placebo. The analyses use different assumptions about treatment discontinuation and other events after randomization, so the numbers should not be treated as identical measures.
The company also reported that 44.4% of participants receiving 6 mg lost at least 20% of their starting body weight. Gastrointestinal symptoms were the most common treatment-emergent adverse events, generally described as mild or moderate. Permanent treatment discontinuation due to adverse events ranged from 0.7% to 1.4% across the active-dose groups, compared with none on placebo.
Earlier Phase 2 results provided another reason to investigate higher doses. In a 36-week study, 8 mg ribupatide produced a mean body-weight reduction of 22.8%, compared with 1.7% for placebo in the treatment-policy analysis, a placebo-adjusted difference of 21.1 percentage points.
These are meaningful randomized human results. They are not proof that ribupatide will produce the same outcomes in the larger, more diverse populations being enrolled globally. The Chinese studies also do not establish superiority over tirzepatide or other approved obesity treatments.
A strong Chinese clinical dataset is a foundation for global development, not a global regulatory label.
The 20 mg Ribupatide Trial Is a Different Bet
The most aggressive part of Kailera’s injection strategy is its high-dose Phase 2b study. That trial enrolled approximately 260 U.S. adults with a body mass index of at least 35 and without type 2 diabetes. It compares weekly doses of 10, 13, 16 and 20 mg with placebo over 48 weeks. Results are expected in mid-2027.
The scientific question is whether increasing receptor stimulation can deliver additional weight loss without causing an unacceptable increase in adverse effects or treatment discontinuations. More exposure is not automatically better treatment. A higher dose that improves average weight loss but causes substantially more patients to stop taking the medicine could be a weak commercial proposition.
For the field’s newer GLP-1/GIP candidates, the race is increasingly about finding an appropriate balance between efficacy, tolerability, convenience and long-term use. Ribupatide will eventually have to compete with a drug class whose clinical evidence, prescribing patterns and supply chains are already established.
Cross-trial comparisons are particularly tempting here. But the Chinese and U.S. studies differ in population, doses and duration, while comparisons with approved drugs involve still more differences. Even if ribupatide posts a striking weight-loss number at 20 mg, that will not be equivalent to a randomized head-to-head comparison with tirzepatide.
Higher dosing may create a differentiator. It may also reveal the limits of the molecule.
Kailera Is Also Developing an Oral Dual Agonist and a Triple Agonist
Kailera’s pipeline extends well beyond its lead injection. The company has an oral formulation of ribupatide, called KAI-9531-T, which it says has completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration. Kailera expects to begin two global Phase 3 trials in the first half of 2027, evaluating once-daily tablets at doses up to 25 mg over 60 weeks.
The oral program gives Kailera a second potential route to market, although a completed FDA meeting does not itself establish that the medicine works or that it will be approved. Oral peptide delivery brings separate questions about absorption, dosing consistency and manufacturing.
Safiglipron, also known as KAI-7535, is a different kind of oral candidate: a small-molecule GLP-1 receptor agonist rather than a peptide dual agonist. Its Phase 2 trial has fully enrolled approximately 300 adults in the United States and Australia. The 44-week study is examining dose escalation and the balance between weight loss and tolerability, with data expected in mid-2027.
The fourth asset, KAI-4729, is an injectable triple agonist designed to activate GLP-1, GIP and glucagon receptors. Kailera reports that its Investigational New Drug application is active with the FDA and that it expects to begin a Phase 1 injection-site and ethnic-bridging study by the end of 2026, with data anticipated in 2027.
These are different clinical programs, with different mechanisms and levels of evidence. The fact that one ribupatide formulation has advanced into pivotal research does not establish the efficacy of the other candidates.
The Financial Risk: $1.04 Billion in Cash and a Mid-2028 Readout
Kailera ended September with $1,037.6 million in cash, cash equivalents and marketable securities. Management expects those resources to support operations into mid-2028, which overlaps with its anticipated Phase 3 ribupatide results.
The spending trajectory shows why the calendar matters. Research and development expenses reached $84.7 million in the third quarter, compared with $27.0 million a year earlier. The company recorded a quarterly net loss of $95.7 million, compared with $39.6 million in the corresponding 2025 period. For the first nine months of 2026, its net loss was approximately $285.8 million.
Those losses reflect clinical development, manufacturing preparation, personnel and the other costs of advancing a portfolio. A net loss is not identical to cash burn, and the company’s reported cash balance does not imply that it will necessarily run out of money in mid-2028. The runway is a management forecast that depends on future spending and other assumptions.
Still, the timing creates a genuine financing question. If the pivotal trials finish on schedule and produce compelling results, Kailera could enter its next strategic phase with valuable data. Delays, additional studies or weaker-than-expected results could put greater pressure on the balance sheet before the company reaches a decision point.
Kailera’s relationship with Hengrui is also part of a larger biotechnology trend: companies developing Chinese-origin incretin assets for global markets. Hengrui is separately developing HRS-1596, an experimental once-weekly oral dual agonist, for which Novo Nordisk announced a licensing agreement in September 2026.
That agreement carries a potential total value of up to $2.6 billion, including $300 million upfront and additional milestone payments. It reflects substantial multinational interest in Chinese metabolic-drug discovery, as Grey Pepper examined in its report on Novo’s Hengrui licensing deal.
The financial challenge is not merely raising enough capital to run clinical trials. It is ensuring that the trials produce commercially useful evidence before the available funding becomes a greater constraint.
The projected runway and the pivotal readout fall in the same part of the calendar. That is a risk worth watching, not a prediction of insolvency.
What to Watch in 2027 and 2028
The next year should provide several opportunities to evaluate Kailera’s pipeline. The company expects its high-dose ribupatide Phase 2b data and safiglipron Phase 2 results in mid-2027. It also plans to begin global Phase 3 development for oral ribupatide during the first half of the year and to report early KAI-4729 data in 2027, assuming its planned study proceeds.
Those milestones could help determine whether Kailera has one strong asset or a broader portfolio of viable obesity treatments. The high-dose results will be particularly important for identifying whether ribupatide has additional efficacy potential without disproportionately worsening tolerability.
The most consequential milestone remains the KaiNETIC Phase 3 program, with data expected in mid-2028. Those studies should provide the global efficacy and safety evidence needed to judge ribupatide more seriously against established GLP-1-based therapies.
Even success would leave a commercial challenge. By 2028, competing obesity drugs may have lower prices, broader insurance coverage, additional indications and years of real-world prescribing experience. A new entrant needs more than a strong number on the scale. It needs a convincing reason for physicians, patients and payers to adopt it.
Kailera has a substantial clinical program, human efficacy data from China and financial resources that management expects to carry it toward the pivotal readout. It has not yet shown that its lead molecule can win in a global market.
The trials are full. The hard wait has begun.
Sources
- Kailera Therapeutics. Third Quarter 2026 Financial Results and Business Updates, November 4, 2026.
- Kailera Therapeutics. Completion of Enrollment in KaiNETIC Global Phase 3 Program, September 30, 2026.
- Hengrui Pharma and Kailera Therapeutics. Additional Data from the GEMINI-1 Phase 3 Trial in China, November 4, 2025.
- Hengrui Pharma and Kailera Therapeutics. Positive Topline Data from Phase 3 Obesity Trial in China, July 15, 2025.
- Novo Nordisk. Novo and Hengrui Pharma Enter Exclusive License Agreement for HRS-1596, September 29, 2026.
